David Kendall

David Kendall has had an active interest in cannabinoid research for over 20 years focussing initially on endocannabinoid signalling in the vascular system and latterly in its roles in pain. He was Professor of Pharmacology in the University of Nottingham Medical School until 2015 before taking up the position of Chief Scientific Officer for the drug discovery company PharmNovo.

David Kendall has had an active interest in cannabinoid research for over 20 years focussing initially on endocannabinoid signalling in the vascular system and latterly in its roles in pain. He was Professor of Pharmacology in the University of Nottingham Medical School until 2015 before taking up the position of Chief Scientific Officer for the drug discovery company PharmNovo. See less